ASX:MSBBiotechs
Mesoblast (ASX:MSB) Is Down 6.4% After Encouraging FDA Feedback On Back Pain Cell Therapy Data – Has The Bull Case Changed?
In January 2026, Mesoblast reported that the FDA’s review of Phase 3 data for its cell therapy rexlemestrocel-L in chronic discogenic low back pain found pain outcomes favoring the active treatment and confirmed that 12‑month pain reduction could support a future Biologics License Application.
The FDA also indicated that robust opioid reduction data from Mesoblast’s trial might be reflected in product labeling, highlighting the therapy’s potential relevance to chronic pain management during...